It should be highlighted that another recent study has demonstrated the efficacy of the pan-PI3K inhibitor, NVP-BKM120, in pre-clinical models of Ph+ B-ALL [52]. The gene discussed is PIK3CD; the disease is acute lymphoblastic leukemia.